Longer Travel Time to Prostate Cancer Treatment Linked to Lower Mortality
A national cohort study in prostate cancer found an unexpected pattern: men who traveled 30 minutes or longer to their treatment facility had lower mortality than those living closer to care. The finding runs against the usual assumption that geographic proximity automatically improves cancer outcomes, and it raises a harder question about what patients gain when care is concentrated in specialized centers rather than delivered near home.
The analysis used data from the Multilevel Epidemiologic Tumor Registry for Oncology, a population-based cancer registry that links masked residential and treatment facility information across multiple US state registries. Men aged 40 to 99 years diagnosed with prostate cancer between January 1, 2000, and December 31, 2015, were included, with follow-up extending through January 1, 2018. In total, 159,943 men formed the study cohort, with a mean age of 66.3 years and median follow-up of 101.2 months.
A single sentence captures the central result: longer travel time was associated with lower mortality.
Travel burden was estimated from masked geocodes and road network data rather than straight-line distance, an important distinction because actual road travel better reflects the burden patients face when reaching treatment. Men were categorized by estimated travel time of less than 30 minutes versus 30 minutes or longer. Just 44.1% were in the shorter-travel group, while 55.9% faced longer travel times. Despite that added distance, the longer-travel group had a lower risk of death from any cause, with an adjusted hazard ratio of 0.91 and a 95% confidence interval of 0.89 to 0.93. Prostate cancer-specific mortality also favored the longer-travel group, with an adjusted hazard ratio of 0.90 and a 95% confidence interval of 0.86 to 0.95.
Why More Distance May Track With Better Outcomes
The most plausible explanation is not that travel itself protects patients. The biological and systems-level logic points in the opposite direction: men willing or able to travel farther may be reaching higher-volume facilities, where diagnostic workup, risk stratification, and multimodal treatment are more standardized. In prostate cancer, the quality of initial staging and definitive treatment selection can shape long-term survival for years. Centralized centers are also more likely to concentrate radiation oncology expertise, surgical volume, pathology review, and access to multidisciplinary management, all of which can reduce undertreatment or inconsistent follow-up.
Distance can therefore behave as a proxy for where care is delivered, not just how far a patient lives from it. A patient who travels 45 minutes to a major referral center may receive more guideline-concordant therapy than a patient treated closer to home in a lower-volume setting. In that sense, the travel-time signal may reflect the advantages of specialization, not the burden of the commute.
At the same time, the result should not be mistaken for a recommendation to send everyone farther from home. Access barriers remain real. Transportation limitations can delay consultation, complicate repeated visits for radiation or surveillance, and contribute to missed diagnoses in the first place. Men with fewer resources may never enter the cohort of patients who can travel to high-performing centers, which means the observed association may partly reflect selection rather than a direct causal benefit of distance.
Mortality Differences Across a Large, Diverse Registry Cohort
The registry drew from Hawaii, Louisiana, Massachusetts, New Jersey, Ohio, Utah, and Washington, including Seattle and Puget Sound areas, giving the analysis a broader geographic footprint than single-center experience. That national representation matters because prostate cancer care varies widely by region, facility type, and local referral patterns. The cohort also spanned diagnoses made over a 15-year period, allowing enough follow-up to observe survival differences that would be invisible in short-term analyses.
Follow-up was long enough to capture both overall and disease-specific death, and the mortality separation persisted across most subgroups. The abstract does not provide a full list of subgroup definitions, but the consistency across strata suggests the association was not driven by a single isolated population. Even so, the results remain observational. Cox proportional hazards modeling can adjust for measured factors, but it cannot fully eliminate confounding by disease severity, socioeconomic status, treatment selection, or facility quality.
The timing of prostate cancer care adds another layer of interpretation. Early diagnostic pathways may be especially sensitive to referral patterns, and later treatment decisions often hinge on whether a patient reaches a center with broader expertise. If men who lived farther away were systematically more likely to reach specialty care, the association could reflect better staging, more appropriate use of surgery or radiation, or closer alignment with evidence-based treatment pathways.
Access Barriers Remain Part of the Clinical Equation
A shorter commute does not guarantee better cancer care, and a longer commute does not automatically harm survival. In this cohort, proximity to treatment was not the advantage it might seem to be. What matters clinically is not just nearness, but the quality and coordination of the care delivered once a patient arrives.
The study also leaves open a practical concern: patients with limited transportation may face the opposite problem, delayed diagnosis or inconsistent follow-up. Travel time can become a barrier to biopsy, staging, definitive therapy, and surveillance, especially for older men or those with competing medical issues. A survival advantage among longer-travel patients should therefore be read alongside the possibility that some men closer to treatment facilities are still receiving care in settings with less specialization, rather than better access.
For clinicians, the implication is straightforward even if the epidemiology is not. Referral geography may be masking differences in treatment quality. Men with prostate cancer may benefit when complex decisions are concentrated in centers with higher expertise, but health systems must still confront transportation, delayed presentation, and unequal access to specialty evaluation. The study does not settle whether centralization should be expanded, but it does show that proximity alone is a poor surrogate for quality in this disease.
The work ends with an uncomfortable but useful signal: a shorter drive did not translate into better survival, and in this cohort the opposite association appeared instead. That finding should prompt closer scrutiny of where men with prostate cancer are treated, how quickly they enter the system, and whether the nearest facility is also the most effective one.